Cancer R&D has never been more promising. Yet pricing and access to this new world of cancer therapy remains thorny. These issues have to be resolved if society is going to reap the benefits of this work. Come hear from some of the leading scientists, entrepreneurs, and investors about how they are thinking about the future. All ticket proceeds go to support cancer research at Fred Hutch.

NOTE: Last year’s event sold out in advance, and space is limited. Buy your tickets early to save your seat.

AGENDA

1:00 p.m. | Registration

1:30 p.m. | Welcome Remarks

• Rana Strellis, SVP for global communications and culture, Alexion Pharmaceuticals
• Luke Timmerman

1:35 p.m. | Why I'm Doing Kilimanjaro Climb to Fight Cancer (60 seconds each)

• Uciane Scarlett, associate, Atlas Venture
• Katrine Bosley, biotech entrepreneur
• Praveen Tipirneni, CEO, Morphic Therapeutic
• Deaidra Smith, Director of Portfolio Communications, Alexion Pharmaceuticals

1:40 p.m. | New Ideas for Cancer Treatment (10 minute slide presentations)

• Simba Gill, Evelo Biosciences (monoclonal microbials for cancer)
• Karen Akinsanya, chief biomedical scientist, Schrodinger
• Sanjiv Patel, Relay Therapeutics, (computational drug discovery)
• Art Krieg, Checkmate Pharmaceuticals (CpG oligonucleotides)
• Tariq Kassum, Obsidian Therapeutics (tunable T-cell therapies)
• Leigh Zawel, Cullinan Oncology (portfolio of platforms & mechanisms)

2:50 p.m. | Cancer Investment Landscape. Separating the Hype from the Reality.

• Elliott Sigal, venture partner, NEA
• Phil Rowlands, Head, Oncology Therapeutic Area Unit, Takeda 
• Doug Cole, managing partner, Flagship Pioneering (moderator)

3:20 p.m. | BREAK

3:40 p.m. | Where to Focus? A View from Pharma

• Paul Biondi, SVP, business development and strategy, Bristol-Myers Squibb
• John Reed, EVP, global head of R&D, Sanofi
• Kate Haviland, Blueprint Medicines (moderator)

4:00 p.m. | How to Make It Easier for Patients to Get Access to New Therapies?

• Zoe Barry, CEO, ZappRx
• Richa Wilson, Genentech/Roche, digital partnerships
• Simon Kennedy, CEO, TriAxia Health (moderator)

4:30 p.m. | What’s a Fair Way to Pay for All This?

• Jeff Berkowitz, CEO, Real Endpoints
• Leora Schiff, principal, Altius Strategy Consulting

5:00 p.m. | Closing Conversation on the Future for Cancer Care

• David Schenkein, executive chairman, Agios Pharmaceuticals; general partner GV
• Mary Lynne Hedley, co-founder and president, TESARO
• Cindy Perettie, CEO, Foundation Medicine
• Deb Palestrant, partner, 5AM Ventures; head of 4:59 (moderator)

5:30 p.m. | A Word on the Kilimanjaro Climb to Fight Cancer

• Luke Timmerman

5:35 p.m. | NETWORKING

6:00 p.m. | END 

Sponsors:

• Veracyte
• Nektar Therapeutics
• Alexandria Real Estate Equities 
• Takeda Pharmaceuticals
• Foundation Medicine
• Madryn Asset Management
• Servier
• Sofinnova
• ATUM Bio
• 5AM Ventures
• Pfizer
• Blueprint Medicines
• Alexion